Clinical and laboratory characteristics of hepatitis C and COVID‐19 coinfection: Prolonged RNA shedding in nonhospitalized case

Villar, Lívia Melo; Paula, Vanessa Salete de; Pinto, Laura Cristina Machado; Marques, Bianca Cristina Leires; Costa, Vanessa Duarte da; Silva, Lucas Lima da; Santos, Alanna Calheiros; Nascimento, Giselle Prado do; Miguel, Juliana Custódio; Mendonça, Ana Carolina da Fonseca; Motta, Fernando Couto; Lewis‐Ximenez, Lia Laura

doi:10.1002/ccr3.3877

Cited by 4 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has now become the dominant cause of COVID-19 in the world.SARS-CoV-2 might cause hepatitis B virus (HBV) reactivation 3 ; however, the interaction between HCV and SARS-CoV-2 has rarely been described. One case report described no significant change in HCV RNA titer after COVID-19 infection in a nonhospitalized patient 4. Here, we report a case that HCV RNA might be significantly elevated afterCOVID-19 infection in hospitalized patients, and HCV viremia flare up might occur after COVID-19 infection.…”

mentioning

confidence: 61%

“…One case report described no significant change in HCV RNA titer after COVID‐19 infection in a nonhospitalized patient. 4 Here, we report a case that HCV RNA might be significantly elevated after COVID‐19 infection in hospitalized patients, and HCV viremia flare up might occur after COVID‐19 infection. In the previous literature, the mean change of viral load was less than 1 log 10 per year and rarely exceeded 2 log 10 .…”

mentioning

confidence: 85%

See 1 more Smart Citation

Suppression of hepatitis C virus replication during COVID‐19 infection

Jang

2022

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

mentioning

confidence: 61%

mentioning

confidence: 85%

Suppression of hepatitis C virus replication during COVID‐19 infection

Jang

2022

The Kaohsiung J of Med Scie

View full text Add to dashboard Cite

“…Recent studies reveal an association between high viral load and the severity of the disease. 15 In particular, in the SARS‐CoV‐2/HCV coinfected patients, a prolonged RNA shedding was observed, 16 thereby increasing their chances of developing severe immune suppression. Hence, in comparison with the non‐HCV‐infected patients, the ones with SARS‐CoV‐2/HCV coinfection had a higher viral load and a delayed recovery from the disease.…”

Section: Discussionmentioning

confidence: 99%

Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and hepatitis C virus

León

Silva

Santos

et al. 2022

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection can generate a systemic inflammatory response, characterized by a cytokine storm and associated with an exaggerated release of proinflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and IL-17, all of which can affect the liver. Here, we aimed to evaluate the cytokine profiles of patients suffering from coronavirus disease (COVID)-19 and/or hepatitis. We subjected 87 patients to serology and/or polymerase chain reaction analysis for the hepatitis C virus. They were also tested for TNF-α, IL-6, and IL-17 using commercial immunoassay kits. The test results of the COVID-19/hepatitis C patients (n = 8) were compared with that of the negative controls (n = 28), hepatitis C patients (n = 29), and COVID-19 patients (n = 22). All expressed high levels of cytokines. The COVID-19/hepatitis patients exhibited higher levels of IL-6 (6.33 ± 3.9 pg/ml) and IL-17 (102.23 ± 2.7 pg/ml); however, TNF-α values were lower (68.08 ± 15.88 pg/ml), as compared with that of the hepatitis patients (p < 0.001), and lower than that of the COVID-19 patients and exceptionally for TNF-α (p < 0.05). These data highlight the importance of monitoring patients with hepatitis and COVID-19.

show abstract

“…In HCV patients with liver cirrhosis, the severity and mortality during coinfection with SARS-CoV-2 were increased [ 66 ]. A case report indicates that the SARS-CoV-2 RNA shedding is prolonged in the coinfection [ 67 ]. However, due to limited data reported for HCV and SARS-CoV-2 coinfection, T cell involvement in these cases is still under ambiguous investigation.…”

Section: Role Of T Cells During Coinfection With Viruses Bacteria And...mentioning

confidence: 99%

T Cell Response to SARS-CoV-2 Coinfection and Comorbidities

et al. 2023

View full text Add to dashboard Cite

For the past three years, COVID-19 has become an increasing global health issue. Adaptive immune cells, especially T cells, have been extensively investigated in regard to SARS-CoV-2 infection. However, human health and T cell responses are also impacted by many other pathogens and chronic diseases. We have summarized T cell performance during SARS-CoV-2 coinfection with other viruses, bacteria, and parasites. Furthermore, we distinguished if those altered T cell statuses under coinfection would affect their clinical outcomes, such as symptom severity and hospitalization demand. T cell alteration in diabetes, asthma, and hypertension patients with SARS-CoV-2 infection was also investigated in our study. We have summarized whether changes in T cell response influence the clinical outcome during comorbidities.

show abstract

Clinical and laboratory characteristics of hepatitis C and COVID‐19 coinfection: Prolonged RNA shedding in nonhospitalized case

Abstract: Nonhospitalized COVID‐19 and hepatitis C‐coinfected patient presented prolonged RNA shedding and mild course of infection. This finding demonstrated the importance of long follow‐up of these patients.

Cited by 4 publications

References 27 publications

Suppression of hepatitis C virus replication during COVID‐19 infection

Suppression of hepatitis C virus replication during COVID‐19 infection

Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and hepatitis C virus

T Cell Response to SARS-CoV-2 Coinfection and Comorbidities

Contact Info

Product

Resources

About